What are the adverse reactions of Binimetinib?

In clinical studies of binimetinib in combination with canafenib to treat melanoma or non-small cell lung cancer , the most common (≥25%) adverse reactions were fatigue, nausea, diarrhea, vomiting, musculoskeletal pain, vomiting, abdominal pain, visual impairment, constipation, dyspnea, rash, and cough. Serious adverse reactions (≥2%) include bleeding, diarrhea, anemia, dyspnea, pneumonia, cardiac arrhythmia, device-related infection, edema, myocardial infarction, and pleural effusion.

Based on findings from animal reproduction studies and its mechanism of action, bimetinib can cause fetal damage when taken by pregnant women. In animal reproduction studies, oral bimetinib was embryotoxic in rabbits during organogenesis and is an abortifacient at doses greater than or equal to those resulting in exposures approximately 5 times the human exposure at a clinical dose of 45 mg twice daily. No overall differences in the safety or effectiveness of bimetinib plus canelfenib were observed in older patients compared with younger patients. Because bimetinib is 97% bound to plasma proteins, hemodialysis may not be effective in patients who overdose on bimetinib. Carcinogenicity studies with bimetinib have not been performed. Bimetinib was not genotoxic in studies assessing bacterial reverse mutations, chromosomal aberrations in mammalian cells, or rat bone marrow micronuclei.

The original drug bimetinib has not yet been launched in China, and therefore is not covered by medical insurance. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.